These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22807204)

  • 21. Sequential monitoring of clinical trials with multiple survival endpoints.
    Williams PL
    Stat Med; 1996 Nov 15-30; 15(21-22):2341-57; discussion 2367-70. PubMed ID: 8931205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sample size determination using an interim analysis.
    Bristol DR
    J Biopharm Stat; 1993 Sep; 3(2):159-66. PubMed ID: 8220401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interim analysis: the alpha spending function approach.
    DeMets DL; Lan KK
    Stat Med; 1994 Jul 15-30; 13(13-14):1341-52; discussion 1353-6. PubMed ID: 7973215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Truncated robust distance for clinical laboratory safety data monitoring and assessment.
    Lin X; Parks D; Zhu L; Curtis L; Steel H; Rut A; Mooser V; Cardon L; Menius A; Lee K
    J Biopharm Stat; 2012; 22(6):1174-92. PubMed ID: 23075016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternatives to the standard Fleming, Harrington, and O'Brien futility boundary.
    Anderson JR; High R
    Clin Trials; 2011 Jun; 8(3):270-6. PubMed ID: 21441286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring accumulating data in a clinical trial.
    Berry DA
    Biometrics; 1989 Dec; 45(4):1197-211. PubMed ID: 2611322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
    Dallas MJ
    J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An adaptive approach to implementing bivariate group sequential clinical trial designs.
    Todd S
    J Biopharm Stat; 2003 Nov; 13(4):605-19. PubMed ID: 14584711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and monitoring of multi-arm multi-stage clinical trials.
    Ghosh P; Liu L; Senchaudhuri P; Gao P; Mehta C
    Biometrics; 2017 Dec; 73(4):1289-1299. PubMed ID: 28346823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
    Thorlund K; Devereaux PJ; Wetterslev J; Guyatt G; Ioannidis JP; Thabane L; Gluud LL; Als-Nielsen B; Gluud C
    Int J Epidemiol; 2009 Feb; 38(1):276-86. PubMed ID: 18824467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Group sequential designs using a family of type I error probability spending functions.
    Hwang IK; Shih WJ; De Cani JS
    Stat Med; 1990 Dec; 9(12):1439-45. PubMed ID: 2281231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coupled error spending functions for parallel bivariate sequential tests.
    Cook RJ
    Biometrics; 1996 Jun; 52(2):442-50. PubMed ID: 8672698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.